Navigation Links
Lilly Reports Second-Quarter 2011 Results
Date:7/21/2011

he partial impairment of the acquired in-process research and development asset related to liprotamase, partially offset by gains on the disposition of investment securities.

The effective tax rate was 21.8 percent in the second quarter of 2011, compared with an effective tax rate of 22.3 percent in the second quarter of 2010. This decrease was driven primarily by the lapse of the U.S. R&D tax credit, which resulted in an increase in the 2010 effective tax rate. The lower tax rate for the second quarter of 2011 reflects reinstatement of the U.S. R&D tax credit for 2010 and 2011 during the fourth quarter of 2010.

Net income and earnings per share decreased to $1.197 billion and $1.07, respectively, compared with second-quarter 2010 net income of $1.349 billion and earnings per share of $1.22. The decreases in net income and earnings per share were primarily driven by lower operating income, partially offset by a lower effective tax rate.

Second-Quarter 2011 non-GAAP Results

Operating income decreased 3 percent to $1.721 billion, due to increased marketing, selling and administrative expenses and a lower gross margin percent. Net income decreased 4 percent to $1.316 billion, while earnings per share decreased 5 percent to $1.18. These decreases were primarily driven by lower operating income, partially offset by a lower net effective tax rate. Excluding the impact of changes in foreign exchange rates, earnings per share would have decreased approximately 4 percent.

For purposes of non-GAAP reporting, items totaling $.11 and $.02 per share in the second quarters of 2011 and 2010, respectively, have been excluded. For further detail, see the reconciliation below as well as the footnotes to the non-GAAP income statement later in this press release.Second Quarter20112010

% GrowthEarnings per share (reported)$1.07$1.22(12)%Restructuring charges

.11.02Earnings per share (non-GAAP)  $1.18$1.24(5)%Year-to-Date Re
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
2. Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lillys Beamline Capabilities
3. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
4. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
5. Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System
6. Lilly Quality Leader Walsh Appointed to Companys Executive Committee
7. Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
8. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
9. Lilly Declares Third-Quarter 2011 Dividend
10. Lilly for Better Health™ Launches Enhanced Multi-Channel Patient Education Platform
11. Synthes and Lilly Sign Development and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014   Coqui RadioPharmaceuticals Corp. , ... U.S. commercial producer of Molybdenum-99 (Mo-99), is proud to ... INVAP to design its Medical Isotope Production Facility ... is the parent isotope of Technetium-99, which is used ... 2012, Congress passed legislation making it a national priority ...
(Date:11/21/2014)... --  Wellcentive , the industry leader in end-to-end ... today being named one of the four finalists ...  Sponsored by Intel, the world leader in computing ... companies developing leading-edge technology and unique approaches to ... Wellcentive,s Mason Beard , senior vice ...
(Date:11/21/2014)... 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... of $80,000,000 aggregate principal amount of 5.25% Convertible Senior ... offering within the United States . ... pursuant to Rule 144A under the Securities Act of ... granted the initial purchasers an option to purchase up ...
Breaking Medicine Technology:Coqui RadioPharmaceuticals Inks Deal With INVAP 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3
... SWANTON, Vt ., May 7 This May, AllerAir ... their effort to spread Multiple Chemical Sensitivity Syndrome awareness.   , ... AllerAir will make chemical awareness tips ... www.allerair.com .  Additionally, their blogs and articles ...
... A post-hoc analysis of a Phase 3 safety study ... a lower incidence of nausea, vomiting and constipation when compared ... moderate to severe low-back or osteoarthritis pain.  These data will ... Annual Scientific Meeting of the American Pain Society (APS), and ...
Cached Medicine Technology:Multiple Chemical Sensitivities Are Real 2Multiple Chemical Sensitivities Are Real 3Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 2Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 3Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 4Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 5Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 6Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 7Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 8Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 9
(Date:11/23/2014)... 2014 SWAccessControl.com's high quality access control ... the company has announced its new collection of power ... these high quality power suppliers. All the new models ... special offer lasts until Dec. 20, 2014. , SWAccessControl.com ... have been supporting it for a long time. It ...
(Date:11/23/2014)... Falls Church, VA (PRWEB) November 23, 2014 ... and TV Have in Common, **FDAnews On-Demand Webinar**, Dec. ... http://www.fdanews.com/TheFDAisWatchingOnDemand , The FDA’s focus on promotional ... ads. , Now they're looking at websites, ... , Mark the calendar for Thursday, Dec. 11, for ...
(Date:11/22/2014)... Greenville, SC (PRWEB) November 23, 2014 ... back to their communities. AlignLife experience rapid growth in ... upon a very unique opportunity. AlignLife of Simpsonville ... area AlignLife offices for their first annual Toy Drive. ... local charity they would support with this year's toy ...
(Date:11/22/2014)... A classic black prom dress will never go out of ... unveiled its new items of black prom gowns . ... big discount, up to 70% off. People throughout the world ... prom dresses, made with the best materials, can make wearers ... customers, the company provides these beautiful outfits in a huge ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 “Due to my ... an inventor, from Gurnee, Ill. “While using the ice grip ... and I thought there needed to be a safer way ... the SPIKE BLOCK. , The SPIKE BLOCK offers added safety ... it would help to reduce injuries and damage associated with ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
... The Cosmetic Bootcamp, LLC,announces that its annual marketing and ... will begin on Dec. 11, 2008. Despite a ... sponsorship.,According to program chair, Kenneth Beer MD, "We are ... for specialists both by the specialists,and industry." Dr. ...
... resource the necessary information to make an informed decision when ... , , LYNDHURST, N.J., Dec. ... city,s best otolaryngologist (and figuring out what an otolaryngologist is), ... if you,re not an MD, a DO or are certified ...
... Phase II Cancer Trials and the Company,s Other Clinical Programs All ... - Significant Validation Achieved for Bavituximab and Peregrine,s Anti-PS Anti-Viral ... - Company Enters into Loan Agreement for Up to ... TUSTIN, Calif., Dec. 10 Peregrine Pharmaceuticals, Inc. (Nasdaq: ...
... PetFit(TM) Challenge Participant Shows Remarkable Quick Weight Loss Improvement , ... On January 20, Zeb, a 104 pound, 7-year-old, Labrador ... Hill,s PetFit(TM) Challenge participants. At Zeb,s recheck on ... lost 22 pounds and was now at 82 pounds. Dr. ...
... dry skin... much of the time with poor results. During Winter, ... the skin. , ... Denver, CO. (PRWEB) December 10, 2008 -- Winter ... across the country suffering from dry skin problems. According to estimates ...
... Global Med Technologies(R), Inc.,("Global Med" or the "Company") (OTC ... today announced that on,Tuesday, December 9, 2008, its board ... LLC ("VPC") whereby VPC proposed to acquire a,majority share ... proposal received is,as follows: , , ...
Cached Medicine News:Health News:Vitals Launches Free eBook to Help Consumers Find 'Dr. Right' 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 4Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 5Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 6Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 7Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 8Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 9Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 10Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 11Health News:Video: Combined Veterinary and Pet Owner Efforts Help Pet Lose Big 2Health News:Video: Combined Veterinary and Pet Owner Efforts Help Pet Lose Big 3Health News:Top Tips To Naturally Heal Dry Skin And Moisturize This Winter 2Health News:Top Tips To Naturally Heal Dry Skin And Moisturize This Winter 3Health News:Global Med Technologies(R) Inc. Receives Unsolicited Proposal From Victory Park Capital Advisors, LLC 2Health News:Global Med Technologies(R) Inc. Receives Unsolicited Proposal From Victory Park Capital Advisors, LLC 3Health News:Global Med Technologies(R) Inc. Receives Unsolicited Proposal From Victory Park Capital Advisors, LLC 4
Cholesterol FS. For determination of cholesterol in serum or plasma. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P Trulab L....
Intended for the quantitative determination of total cholesterol in serum. Reaction: Endpoint. Reaction complete within five minutes. Wavelength: 500 nm. Linearity: 700 mg/dL (18.1 mmol/L). Single st...
This 16-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
... SE is a major upgrade ... of important physical and software ... operation and increase efficiency. The ... Generation" ACS:180. The productivity of ...
Medicine Products: